Patient not adequately controlled with insulin therapy and hospitalized for congestive heart failure

Abstract

The data provided by cardiovascular safety studies of type 2 sodium-glucose transporter inhibitors have aroused great interest among diabetologists and other specialists. They demonstrated that these drugs reduce significantly, compared to placebo, the risk of major cardiovascular events, all cause and cardiovascular mortality, and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk. We report the case of a cardiovascular diabetic patient not adequately controlled by high-dose multi-injective insulin therapy and hospitalized for congestive heart failure, treated with empagliflozin in association with high doses of loop diuretic (furosemide) and sacubitril/valsartan (Diabetology).

Keywords

• Type 2 diabetes
• Congestive heart failure
• Empagliflozin